Active Watch List: INSYS Therapeutics (NASDAQ:INSY), Celladon Corporation (NASDAQ:CLDN), WisdomTree Investments, Inc. (NASDAQ:WETF), Arotech Corporation (NASDAQ:ARTX), DigitalGlobe, Inc. (NYSE:DGI)

Insys Therapeutics, Inc. (NASDAQ:INSY) announced that the FDA has granted orphan drug status to its pharmaceutical cannabidiol (CBD), for the treatment of glioblastoma multiforme (GBM.V). Glioblastoma multiforme is the most common and aggressive form of malignant primary brain tumor. INSYS Therapeutics, Inc. (NASDAQ:INSY) belongs to Healthcare sector. Its net profit margin is 31.70% and weekly performance is -4.03%. On last trading day company shares ended … Continue reading Active Watch List: INSYS Therapeutics (NASDAQ:INSY), Celladon Corporation (NASDAQ:CLDN), WisdomTree Investments, Inc. (NASDAQ:WETF), Arotech Corporation (NASDAQ:ARTX), DigitalGlobe, Inc. (NYSE:DGI)

Watch List : Denbury Resources (NYSE:DNR), Celladon (NASDAQ:CLDN), Comerica (NYSE:CMA), Post Properties (NYSE:PPS), Bob Evans Farms (NASDAQ:BOBE)

Denbury Resources (NYSE:DNR) posted its quarterly earnings results on Wednesday. The company reported $0.26 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.27 by $0.01, AR Network reports. The company had revenue of $669.00 million for the quarter, compared to the consensus estimate of $628.06 million. Denbury Resources Inc. (NYSE:DNR) belongs to Basic Materials sector. Its net profit margin is 14.80% and … Continue reading Watch List : Denbury Resources (NYSE:DNR), Celladon (NASDAQ:CLDN), Comerica (NYSE:CMA), Post Properties (NYSE:PPS), Bob Evans Farms (NASDAQ:BOBE)

Celladon Corporation (NASDAQ:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, on 07 July 2014 announced it has launched two new clinical development initiatives for MYDICAR(R), its lead product candidate, in patients with end-stage renal disease (ESRD) undergoing surgery for arteriovenous fistula (AVF) creation in preparation for hemodialysis, and in advanced heart failure … Continue reading Stocks to Watch – Celladon Corp (NASDAQ:CLDN), West Marine (NASDAQ:WMAR), Avnet (NYSE:AVT) , ChinaCache Internatnl Hldgs Ltd (ADR) (NASDAQ:CCIH)

Celladon Corporation (NASDAQ:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, on 07 July 2014 announced that it has launched two new clinical development initiatives for MYDICAR(R), its lead product candidate, in patients with end-stage renal disease (ESRD) undergoing surgery for arteriovenous fistula (AVF) creation in preparation for hemodialysis, and in advanced heart … Continue reading Active Watch List – Celladon Corp (NASDAQ:CLDN), World Acceptance Corp. (NASDAQ:WRLD) , Associated Banc Corp (NASDAQ:ASBC) , NN, Inc. (NASDAQ:NNBR)

Celladon Corporation (NASDAQ:CLDN) was a big mover last session, as its shares rose nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the downtrend for the healthcare company since March 24, as the stock is down nearly 25%. Celladon Corp (NASDAQ:CLDN) stock performance was -7.72% in last session and … Continue reading Biotech Touched New Lows: Celladon (NASDAQ:CLDN), MediciNova (NASDAQ:MNOV), Mediwound (NASDAQ:MDWD), Celsion Corporation (NASDAQ:CLSN)

Fate Therapeutics, Inc. (NASDAQ:FATE) announced that it has enrolled the first patient in its phase II study (PUMA − P rohema in UM bilical cord blood transplant in A dults) on Prohema. Fate Therapeutics Inc. (NASDAQ:FATE) stock performance was 27.14% in last session and finished the day at $11.15. Traded volume was 295,227.00 shares in the last session and the average volume of the stock … Continue reading Biotech Stocks New Highs: Fate Therapeutics (NASDAQ:FATE), Synthetic Biologics (NYSEMKT:SYN), Celladon Corp (NASDAQ:CLDN), Kindred Biosciences (NASDAQ:KIN)